[Immunocorrection in the combined treatment of patients with osteomyelitis developing following combined injuries to the maxillofacial and craniocerebral areas].
Grigoriants. L A LA; Zuev. V P VP; Rakhmetov. B R BR; Eremeev. V V VV; Abramova. Z P ZP; Litvinova. L L LL
Key Findings
- Thymogen was given to half of the osteomyelitis patients as part of a combined therapy regimen
- These patients showed weak T‑cell immunity, high NK‑cell counts, and increased inflammatory cytokines
- Thymogen treatment normalized immune markers and boosted overall treatment success
Practical Outcomes
- Thymogen may have immune‑boosting and anti‑inflammatory effects, but the evidence comes from a niche clinical setting. Biohackers should treat this as preliminary data and not adopt it as a routine supplement without further research or medical guidance.
Summary
In a small study of people with bone infection after serious facial and brain injuries, adding the peptide drug thymogen to their treatment helped bring their immune system back toward normal and improved overall recovery, but the findings are limited to a very sick group and not directly tested in healthy individuals.
Abstract
Twenty-one of the forty-two patients with osteomyelitis developing after a combined maxillofacial and craniocerebral injury were administered thymogen, an immunocorrective drug, as a component of combined therapy; immunologic indications for the prescription of such an agent were present in all these patients. Depressed T-cellular immunity was the principal disorder of the immunologic reactivity of this patient population; they also developed elevated counts of NK cells and increased interleukin synthesis by the macrophages, this reflecting a high activity of inflammation. Thymogen therapy was conducive to normalization of the immunologic and nonspecific reactivity and enhanced the treatment efficacy on the whole.
Study Information
pubmed
1991